Impact of Serial Serum Free Light Chain Measurements on Response and Progression Assessments in Multiple Myeloma Patients with Measurable Disease

Introduction: Uniform assessment of response to treatment is crucial to managing myeloma and developing new therapies. Measurement of the monoclonal protein (s) secreted by the myeloma cells forms the cornerstone of disease assessment in MM and has primarily been performed by electrophoretic methods in the serum and urine, as well as assessment of free light chains in the serum. According to international myeloma working group (IMWG) guidelines, serial serum-free light chain (sFLC) is included in MM response assessment to define stringent complete response and for evaluating partial response (PR) or progressive disease (PD) in non/oligo-secretory MM. This study aims to determine the added value of serial sFLC measurements in monitoring response and progression in MM with measurable disease by comparing the kinetics of FLC with M spike measured by electrophoresis in serum or urine.

Methods: This retrospective observational study included newly diagnosed MM patients evaluated at Mayo Clinic in Rochester between 2011-2021. All patients had measurable sFLC (involved FLC level ≥ 10mg/dL, with abnormal sFLC ratio) along with measurable M-protein by serum or urine protein electrophoresis at diagnosis. Serial measurements of sFLC and M-protein by electrophoresis (sPEP/uPEP) were prospectively collected from the electronic medical records at different time points. FLC-response and FLC-PD were evaluated based on IMWG criteria.

Results: The study cohort included 839 patients, 52% with measurable M protein by electrophoresis in serum, 27% in both serum and urine, and 21% in urine-only. A significant association was observed between sFLC and electrophoretic response during the induction and at the time of best response (p <.001). Serum FLC showed a comparable response rate of 98% (≥ PR) at the time of best electrophoretic response (p <.001). Ninety-nine percent of early FLC responders eventually achieved an overall response by sPEP/uPEP (p <.001). In the urine-only group, 99% achieved at least a PR by uPEP, and all showed at least a PR based on sFLC. We observed comparable median percentage changes in serial dFLC and urine M-protein, with parallel trends (p <0.001). The correlation coefficients between the change of sFLC and urine M-protein showed a moderate/strong correlation with coefficients (r) of 0.791, 0.597, 0598, 0.545, after cycles 1, 2, 3, 4, respectively, (p < .001). The response for all cohorts was detected earlier by dFLC (median time 1.1 months, 95% CI: 1.06-1.17), in comparison with serum M-protein (1.5 months, 95% CI: 1.40-1.62) and urine M-protein (2.8 months, 95% CI: 2.42-3.10) with p < .001. In the urine-only group, earlier detection of response by dFLC (1.1 months, 95% CI: 1.00-1.2) was observed, compared to urine M-protein (2.4 months, 95% CI: 2.00-2.7) (p <.001). After a median follow-up of 52 (IQR 27.6, 72.3) months, 56% had PD: 62% by s-FLC, 56% by serum M-protein, and 24% by urine M-protein. Among patients with PD by uPEP, all except one patient met sFLC-PD. Within patients with PD, sFLC was the only detectable tumor marker in 12% of cases at the time of the second line of treatment. After four cycles of induction, there was no difference in PFS between VGPR response determined by sFLC, sPEP, and uPEP (p =0.538). The median second-PFS for patients with onlysFLC-PD was similar to those with urine M-protein PD with or without sFLC-PD (HR 1.28, 95% CI =0.77-2.13. p 0.334). However, the median overall survival (OS) from the first relapse was significantly better for patients with onlysFLC-PD than those with urine M-protein PD (HR 1.87, 95% CI =1.07-3.27. p 0.026).

Conclusions: In this study, achieving sFLC-VGPR has a similar impact on PFS as electrophoretic-VGPR after induction, indicating that serial sFLC can potentially replace the requirement for urine M-protein response (< 100mg in 24-hours urine) as part of the electrophoretic-VGPR criteria, as required by IMWG. A similar response rate between sFLC and urine paraprotein confirms the current cutoffs (90% for urine and 50% for dFLC for VGPR) used for response categories for s-FLC. We also observed that in 12% of patients with PD, sFLC was the only marker of progression, highlighting the value of serial s-FLC in monitoring relapse. In conclusion, our study supports the integration of serial sFLC measurements for monitoring response and progression in MM, even with electrophoretic measurable disease.

Dispenzieri:Takeda: Consultancy, Research Funding; HaemaloiX: Research Funding; Pfizer: Research Funding; BMS: Consultancy, Research Funding; Janssen: Research Funding; Alnylam: Research Funding; Alexion: Consultancy, Research Funding. Gertz:Medscape: Honoraria; Alexion: Honoraria; Alnylym: Honoraria; Sanofi: Other: personal fees; Janssen: Other: personal fees; Johnson & Johnson: Other: personal fees; Abbvie: Other: personal fees for Data Safety Monitoring board ; Ionis/Akcea: Honoraria; Astra Zeneca: Honoraria; Dava Oncology: Honoraria; Prothena: Other: personal fees. Kapoor:Kite: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Membership on an entity's Board of Directors or advisory committees; Mustang Bio: Membership on an entity's Board of Directors or advisory committees; GlaxoSmithKline: Membership on an entity's Board of Directors or advisory committees, Research Funding; X4 Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; AbbVie: Membership on an entity's Board of Directors or advisory committees, Research Funding; Pharmacyclics: Membership on an entity's Board of Directors or advisory committees; Karyopharm: Research Funding; BeiGene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Loxo Pharmaceuticals: Research Funding; Amgen: Research Funding; Bristol Myers Squibb: Research Funding; Regeneron: Research Funding; Ichnos: Research Funding; Sanofi: Membership on an entity's Board of Directors or advisory committees, Research Funding; Angitia Bio: Membership on an entity's Board of Directors or advisory committees; CVS Caremark: Consultancy; Keosys: Consultancy. Kourelis:Novartis: Research Funding; Pfizer: Research Funding. Dingli:Regeneron: Consultancy, Honoraria; BMS: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; Genentech: Consultancy; Novartis: Consultancy, Honoraria; MSD: Consultancy, Honoraria; K36 Therapeutics: Research Funding; Sorrento: Consultancy, Honoraria; Apellis: Consultancy, Honoraria, Research Funding; Alexion: Consultancy, Honoraria. Leung:AbbVie: Current holder of stock options in a privately-held company; Checkpoint Therapeutics: Current holder of stock options in a privately-held company. Lin:Bristol-Myers Squibb: Consultancy, Research Funding; Regeneron: Consultancy; Pfizer: Membership on an entity's Board of Directors or advisory committees; Legend: Consultancy; NexImmune: Membership on an entity's Board of Directors or advisory committees; Sanofi: Consultancy; Caribou: Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Research Funding; Janssen: Consultancy, Research Funding; Genentech: Consultancy. Muchtar:Protego: Consultancy. Cook:Geron Corp: Other: Held $600 Geron Stock for one week and sold without profit . Hwa:GSK: Honoraria; Janssen: Honoraria; Pfizer: Other: Consulting fee located to Mayo Research fund; Shield Therapeutics: Honoraria; MultiMedia Medical, LLC: Consultancy. Murray:The Binding Site: Patents & Royalties: Intellectual Property Rignts Licensed with potential royalties. Kumar:Abbvie: Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Membership on an entity's Board of Directors or advisory committees, Research Funding; Sanofi: Research Funding; Novartis: Research Funding; MedImmune/AstraZeneca: Membership on an entity's Board of Directors or advisory committees, Research Funding; KITE: Membership on an entity's Board of Directors or advisory committees, Research Funding; Adaptive: Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Roche: Research Funding; Merck: Research Funding; Janssen: Membership on an entity's Board of Directors or advisory committees, Research Funding; Oncopeptides: Other: Independent review committee participation.